Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of AL-335 with ACH-3102 and Simeprevir
NCT02512562Phase 1Completed
- Sponsor
- Alios BioPharma
- Start
- Jul 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of adafosbuvir in hepatitis C (HCV) (2 arms), sponsored by Alios BioPharma. Primary endpoints: Multiple dose PK Profile, Cmax and AUC: effect of ACH-3102 on AL-335 and metabolites at Day 28, Multiple dose PK Profile, Cmax and AUC: effect of Simeprevir on AL-335 and metabolites at Day 24 and 1 more. Started Jul 2015; status: completed.
02
Drugs
adafosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02512562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02512562.